FIELD: medicine.
SUBSTANCE: aqueous solution is applied that includes compound 22 having the structural formula 
or its pharmaceutically acceptable salt, which is administered to the patient in the form of intravenous infusion, intravenous bolus or subcutaneously, or a pharmaceutical composition containing an effective amount of compound 22, while the specified composition is either dried or is an aqueous solution.
EFFECT: increased efficiency of fungal infection treatment with reduced dosage and frequency of drug administration due to the improved pharmacokinetic profile of the compound.
15 cl, 22 dwg, 14 tbl, 13 ex
| Title | Year | Author | Number |
|---|---|---|---|
| DOSING REGIMENS FOR ECHINOCANDIN CLASS COMPOUNDS | 2013 |
|
RU2719579C2 |
| PERORAL COMPOSITIONS CONTAINING ESTER 17- HYDROXYPROHESTERON, AND CORRESPONDING METHODS | 2012 |
|
RU2640912C2 |
| AMPK LOW-MOLECULAR ACTIVATORS | 2017 |
|
RU2766146C2 |
| CYSTATHIONINE-G-LYASE (CSE) INHIBITORS | 2013 |
|
RU2640418C2 |
| COMPOSITIONS AND METHODS FOR APOLIPOPROTEIN C-III (APOC3) GENE EXPRESSION INHIBITION | 2012 |
|
RU2631805C2 |
| ORAL PHARMACEUTICAL COMPOSITIONS COMPRISING TAXANES AND METHODS FOR TREATMENT USING THEREOF | 1999 |
|
RU2236226C2 |
| PHARMACEUTICAL COMPOSITION FOR ACID LIPOPHILIC COMPOUNDS IN FORM OF SELF-EMULSIFYING COMPOSITION | 1998 |
|
RU2202346C2 |
| COMBINED THERAPY FOR IMMUNE DISEASE TREATMENT | 2004 |
|
RU2329037C2 |
| SELF-EMULSIFYING COMPOSITION FOR LIPOPHILIC COMPOUNDS | 1998 |
|
RU2203648C2 |
| HIGH PENETRATION COMPOSITIONS OR PRODRUGS OF ANTIMICROBIALS AND ANTIMICROBIAL-RELATED COMPOUNDS | 2010 |
|
RU2586287C2 |
